Merck KGaA ends lung cancer vaccine trials
September 12, 2014 at 08:04 AM EDT
FRANKFURT, Sept 12 (Reuters) - German drugmaker Merck KGaA drug stopped all remaining clinical studies of the experimental lung cancer vaccine tecemotide, formerly known as Stimuvax, after renewed attempts to show its effectiveness failed.